These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 32506946)

  • 1. Diabetes and atherothrombosis: The circadian rhythm and role of melatonin in vascular protection.
    Otamas A; Grant PJ; Ajjan RA
    Diab Vasc Dis Res; 2020; 17(3):1479164120920582. PubMed ID: 32506946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interplay between ultrastructural findings and atherothrombotic complications in type 2 diabetes mellitus.
    Soma P; Pretorius E
    Cardiovasc Diabetol; 2015 Jul; 14():96. PubMed ID: 26228646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endothelial dysfunction and platelet hyperactivity in type 2 diabetes mellitus: molecular insights and therapeutic strategies.
    Kaur R; Kaur M; Singh J
    Cardiovasc Diabetol; 2018 Aug; 17(1):121. PubMed ID: 30170601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypofibrinolysis in type 2 diabetes and its clinical implications: from mechanisms to pharmacological modulation.
    Bryk-Wiązania AH; Undas A
    Cardiovasc Diabetol; 2021 Sep; 20(1):191. PubMed ID: 34551784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diabetes mellitus as a prothrombotic condition.
    Grant PJ
    J Intern Med; 2007 Aug; 262(2):157-72. PubMed ID: 17645584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Smoking, haemostatic factors, and cardiovascular risk.
    Leone A
    Curr Pharm Des; 2007; 13(16):1661-7. PubMed ID: 17584096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypofibrinolysis in diabetes: a therapeutic target for the reduction of cardiovascular risk.
    Kearney K; Tomlinson D; Smith K; Ajjan R
    Cardiovasc Diabetol; 2017 Mar; 16(1):34. PubMed ID: 28279217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of oral melatonin treatment on insulin resistance and diurnal blood pressure variability in night shift workers. A double-blind, randomized, placebo-controlled study.
    Hannemann J; Laing A; Middleton B; Schwedhelm E; Marx N; Federici M; Kastner M; Skene DJ; Böger R
    Pharmacol Res; 2024 Jan; 199():107011. PubMed ID: 38029806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Diabetes mellitus and prothrombotic activity].
    Malý J
    Vnitr Lek; 2010 Apr; 56(4):284-8. PubMed ID: 20465096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diabetes mellitus and thrombosis.
    Vazzana N; Ranalli P; Cuccurullo C; Davì G
    Thromb Res; 2012 Mar; 129(3):371-7. PubMed ID: 22197180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BMAL1-Downregulation Aggravates
    Xie M; Tang Q; Nie J; Zhang C; Zhou X; Yu S; Sun J; Cheng X; Dong N; Hu Y; Chen L
    Circ Res; 2020 Mar; 126(6):e15-e29. PubMed ID: 32078488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BβArg448Lys polymorphism is associated with altered fibrin clot structure and fibrinolysis in type 2 diabetes.
    Greenhalgh KA; Strachan MW; Alzahrani S; Baxter PD; Standeven KF; Storey RF; Ariens RA; Grant PJ; Price JF; Ajjan RA
    Thromb Haemost; 2017 Jan; 117(2):295-302. PubMed ID: 27929198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Atherothrombosis in patients with type 2 diabetes mellitus: an overview of pathophysiology].
    Mafrici A; Proietti R
    G Ital Cardiol (Rome); 2010 Jun; 11(6):467-77. PubMed ID: 20922872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New insights into the role of adipose tissue in thrombosis.
    Vilahur G; Ben-Aicha S; Badimon L
    Cardiovasc Res; 2017 Jul; 113(9):1046-1054. PubMed ID: 28472252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic syndrome, haemostasis and thrombosis.
    Alessi MC; Juhan-Vague I
    Thromb Haemost; 2008 Jun; 99(6):995-1000. PubMed ID: 18521499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of insulin dependence on inflammatory process, thrombotic mechanisms and endothelial function, in patients with type 2 diabetes mellitus and coronary atherosclerosis.
    Antoniades C; Tousoulis D; Marinou K; Papageorgiou N; Bosinakou E; Tsioufis C; Stefanadi E; Latsios G; Tentolouris C; Siasos G; Stefanadis C
    Clin Cardiol; 2007 Jun; 30(6):295-300. PubMed ID: 17551966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gender-specific alterations in fibrin structure function in type 2 diabetes: associations with cardiometabolic and vascular markers.
    Alzahrani SH; Hess K; Price JF; Strachan M; Baxter PD; Cubbon R; Phoenix F; Gamlen T; Ariëns RA; Grant PJ; Ajjan RA
    J Clin Endocrinol Metab; 2012 Dec; 97(12):E2282-7. PubMed ID: 22996148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of melatonin in the treatment of type 2 diabetes mellitus and Alzheimer's disease.
    Shen S; Liao Q; Wong YK; Chen X; Yang C; Xu C; Sun J; Wang J
    Int J Biol Sci; 2022; 18(3):983-994. PubMed ID: 35173531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. On the role of coagulation and fibrinolysis in atherosclerosis.
    Juhan-Vague I; Collen D
    Ann Epidemiol; 1992 Jul; 2(4):427-38. PubMed ID: 1342293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronomedicine and type 2 diabetes: shining some light on melatonin.
    Forrestel AC; Miedlich SU; Yurcheshen M; Wittlin SD; Sellix MT
    Diabetologia; 2017 May; 60(5):808-822. PubMed ID: 27981356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.